Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Inhibikase Therapeutics (IKT) EBIAT (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed EBIAT for 6 consecutive years, with -$12.7 million as the latest value for Q4 2025.

  • Quarterly EBIAT fell 4.96% to -$12.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$48.3 million through Dec 2025, down 75.36% year-over-year, with the annual reading at -$48.3 million for FY2025, 75.36% down from the prior year.
  • EBIAT for Q4 2025 was -$12.7 million at Inhibikase Therapeutics, down from -$11.9 million in the prior quarter.
  • The five-year high for EBIAT was -$2.6 million in Q2 2021, with the low at -$13.7 million in Q1 2025.
  • Average EBIAT over 5 years is -$6.4 million, with a median of -$4.6 million recorded in 2022.
  • The sharpest move saw EBIAT tumbled 566.75% in 2021, then grew 15.13% in 2022.
  • Over 5 years, EBIAT stood at -$5.0 million in 2021, then increased by 15.13% to -$4.3 million in 2022, then grew by 2.36% to -$4.2 million in 2023, then tumbled by 190.4% to -$12.1 million in 2024, then decreased by 4.96% to -$12.7 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at -$12.7 million, -$11.9 million, and -$9.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.